Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML

Future Oncol. 2020 May;16(14):887-889. doi: 10.2217/fon-2020-0218. Epub 2020 Apr 27.

Authors

Muhammed Osman Corbali¹, Ahmet Emre Eskazan²

Affiliations

¹ Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
² Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

PMID: 32338053
DOI: 10.2217/fon-2020-0218

No abstract available

Keywords: AML; MDM2 inhibitor; TP53; acute myeloid leukemia; idasanutlin; relapsed or refractory.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor
Drug Resistance, Neoplasm
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / mortality
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors
Pyrrolidines / administration & dosage
Pyrrolidines / adverse effects
Pyrrolidines / therapeutic use*
Recurrence
Retreatment
Treatment Outcome
para-Aminobenzoates / administration & dosage
para-Aminobenzoates / adverse effects
para-Aminobenzoates / therapeutic use*

Substances

Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors
Pyrrolidines
RG7388
para-Aminobenzoates
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2